CLINICAL_TRIALS ClinicalTrials.gov record update

A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04787042
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:08.137169+00:00
Published At: 2024-11-15T00:00:00+00:00
Record Updated At: 2024-11-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cancer", "Solid Tumor", "Melanoma", "Renal Cell Carcinoma", "Triple-negative Breast Cancer", "Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Carcinoma", "MSI-High"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-11-15"
protocolSection.identificationModule.nctId: "NCT04787042"
protocolSection.identificationModule.officialTitle: "A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.